Heptares Therapeutics Limited

Nxera Pharma UK Limited

Other

Julie Elaine Cansfield

Giles Albert Brown

Benjamin Gerald Tehan

Miles Stuart Congreve

Mark Pickworth

Barry John Teobald

Michael Alistair O'Brien

Mark David Rackham

Andrew David Cansfield

Francesca Deflorian

Nigel Alan Swain

Stephen Paul Watson

Michael Alistair O'brien

Gregory R Ott

John Andrew Christopher

Andrea Bortolato

Barry John Teobold

Paul Mcgee

The disclosures herein relate to novel compounds of Formula (1); and salts thereof, wherein A, A, Q, X, R, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

CGRP antagonist compounds

The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

This invention relates to compounds that are agonists of the muscarinic Mreceptor and which are useful in the treatment of muscarinic Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where m, p, q, W, Z, Y, X, X, R, R, Rand Rare as defined herein.

Muscarinic receptor agonists

This invention relates to compounds that are agonists of the muscarinic Mreceptor and/or Mreceptor and which are useful in the treatment of muscarinic M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R, R, R, Rand Rare as defined herein.

Muscarinic agonists

This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R-Rare as defined herein.

Muscarinic M1 receptor agonists

This invention relates to compounds that are agonists of the muscarinic Mand/or Mreceptor and which are useful in the treatment of diseases mediated by the muscarinic Mand Mreceptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (1) wherein X; X; Rand Rare as defined herein.

Pharmaceutical compounds

This invention relates to compounds that are agonists of the muscarinic Mreceptor and/or Mreceptor and which are useful in the treatment of muscarinic M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R, R', R, Rand Rare as defined herein.

This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R-Rare as defined herein. 

This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R, R, Rand Rare as defined herein. 

Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor

This invention relates to compounds that are agonists of the muscarinic Mreceptor and/or M4 receptor and which are useful in the treatment of muscarinic M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R, R, R, Rand Rare as defined herein. 

Growing community of inventors

Cambridge, United Kingdom

Julie Elaine Cansfield